Navigation Links
Thoratec Reports 44 Percent Increase in Second Quarter Revenues;
Date:7/31/2008

To

(in thousands)

Gross profit on a GAAP basis 58% 59%

Share-based compensation expense:

- Cost of product sales 1% 1%

Gross profit on a non-GAAP basis 59% 60%

Diluted net income/(loss) per share

reconciliation For the Fiscal Year Ended 2008

From To

(in thousands, except per share data)

Diluted net income (loss) per share on a

GAAP basis $0.20 $0.26

Share-based compensation expense 0.20 0.20

Amortization of purchased intangibles 0.21 0.21

Income tax effect of non-GAAP

adjustments (0.14) (0.15)

Diluted net income per share on a

non-GAAP basis $0.47 $0.52

Shares used in calculation of diluted

net income (loss) per share -- GAAP 62,801 62,801

Shares used in calculation of

diluted net income per share -- non-

GAAP (a) 62,801 62,801

(a) Shares used in the per share calculation for reconciling items

between GAAP and non-GAAP financial measures.

Thoratec is a world leader in therapies to address advanced stage heart failure. The company's product lines include the Thoratec(R) VAD and HeartMate LVAS with nearly 12,000 devices implanted in patients suffering from heart failure. Additionally, its International Technidyne Corporation (ITC) Division supplies point-of-care blood testing and skin incision products. Thoratec is headquartered in Pleasanton, California. For more information, visit the company's web sites at

SOURCE Thoratec Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. Thoratec Schedules Second Quarter 2008 Conference Call, Webcast
2. Thoratec Schedules First Quarter 2008 Conference Call, Webcast
3. Thoratec Announces Unanimous FDA Advisory Panel Recommendation for Approval of HeartMate II(R) for Bridge-to-Transplantation
4. URGENT Thoratec Corporation Worldwide Recall of Implantable Ventricular Assist Device
5. Thoratecs ITC Division Receives FDA Warning Letter
6. Thoratec Schedules Third Quarter Conference Call, Webcast
7. HCA Reports Second Quarter 2008 Results
8. Encision Reports First Fiscal Quarter Results
9. Osteotech Reports 2008 Second Quarter Diluted Earnings Per Share of $.10 on Revenues of $27.6 Million
10. Orchid Cellmark Reports Second Quarter 2008 Financial Results
11. Nutraceutical Reports Q3 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... from Comfort & Harmony was featured at ... Association (USLCA) May 2nd – 5th. The conference hosted ... , The USLCA annual conference is a trade ... about the latest trends in lactation. , Mombo ... new mothers use to help support infants while breastfeeding. ...
(Date:5/20/2013)... 2013 Mirena IUD lawsuit ... litigation recently established in U.S. District Court, Southern District ... to court records, the litigation’s first Status Conference was ... Plaintiff’s leadership positions were discussed. So far, at ... District of New York, all of which allege that ...
(Date:5/20/2013)... 2013 Co-founder of Atlanta SEO ... keynote speaker at the 5th International INVEST Domaining & ... brings together company representatives and independent individuals from around ... marketing and investments. , The 2013 conference will take ... México from May 20 to 21. A networking city ...
(Date:5/20/2013)... Nearly 20 percent of kidneys that are recovered ... transplant due to factors ranging from scarring in small ... organ going too long without blood or oxygen. But, ... be "recycled" to help solve the critical shortage of ... Center and colleagues, reporting in the journal Biomaterials ...
(Date:5/20/2013)... 2013 Horizon NJ Health, New Jersey’s ... that it has earned a Commendable Accreditation status ... NJ Health is a wholly owned subsidiary of Horizon ... NCQA Health Plan Accreditation is a nationally recognized program ... health plans provide to their members. Health Plan Accreditation ...
Breaking Medicine News(10 mins):Health News:Comfort & Harmony™ Exhibited mombo™ Nursing Pillow at USLCA’s First Inaugural Conference 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Reports on First Status Conference in Federal Mirena Litigation 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Reports on First Status Conference in Federal Mirena Litigation 3Health News:EverSpark CEO to be Keynote Speaker at 5th International INVEST Domaining & Internet Marketing Conference in Mexico City 2Health News:Study suggests new source of kidneys for transplant 2Health News:Horizon NJ Health Awarded Commendable Accreditation by NCQA 2Health News:Horizon NJ Health Awarded Commendable Accreditation by NCQA 3
... ST. LOUIS, Nov. 10 KV Pharmaceutical Company,(NYSE: KVa/KVb) ... previously announced, the Company will be delayed in the ... fiscal 2009. The Company expects to,file a Form 12b-25 ... on Wednesday, November 12, 2008., About KV Pharmaceutical ...
... Left-handed pitcher Jon Lester, who,came back from an off-season ... Boston Red Sox in the 2007 World Series, will ... to a Major League Baseball player,who best exemplifies the ... on and off the field., The 24-year-old Tacoma, ...
... analysis of 33 research projects , , MONDAY, Nov. 10 (HealthDay ... as beta blockers has concluded that they are not useful ... using beta blockers for non-coronary surgery may actually increase the ... conducted the study -- known as a meta-analysis -- recommend ...
... cardiopulmonary bypass does not cause short-term neurological problems ... complex heart defects, according to pediatric researchers. The ... showed adverse neurological effects after newborn surgery for ... news for school-aged children who receive surgery for ...
... 10 A Guide to Implementing,GASB 45, a new issue ... how North Carolina local governments are meeting their,obligations to report ... which is based on a survey of the 30 local ... reports that:, -- 88 percent of the ...
... Net Revenue Increased 93.6% to US$146.5 million; Non-GAAP Gross Margins ... ... 10 /Xinhua-PRNewswire-FirstCall/ -- Mindray,Medical International Limited (NYSE: MR ), a ... selected,unaudited financial results for the third quarter and nine months ended,September ...
Cached Medicine News:Health News:KV Pharmaceutical to File Form 12b-25 on November 12, 2008 2Health News:KV Pharmaceutical to File Form 12b-25 on November 12, 2008 3Health News:KV Pharmaceutical to File Form 12b-25 on November 12, 2008 4Health News:Red Sox Pitcher Jon Lester Wins 2008 Hutch Award(R) 2Health News:Beta Blocker Use Questioned in Non-Heart Surgery 2Health News:Beta Blocker Use Questioned in Non-Heart Surgery 3Health News:No drop in IQ seen after bypass for child heart surgery 2Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 2Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 3Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 4Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 5Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 6Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 7Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 8Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 9Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 10Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 11Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 12Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 13Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 14Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 15Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 16Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 17Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 18Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 19Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 20Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 21Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 22Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 23
(Date:5/20/2013)... BETHESDA, Md. , May 20, 2013  TNI ... diseases through the activation and mobilization of the body,s ... trading on the OTC Markets, OTCQB marketplace under the ... able to view the real-time Level II stock quotes ... Noreen Griffin , CEO of TNI BioTech, ...
(Date:5/20/2013)... Ill. , May 20, 2013  AbbVie ... initiation of a Phase 3 clinical study called ... assess the effects of the investigational compound atrasentan - ... of kidney disease in patients with stage 2 ... 2 diabetes.  SONAR is a large, multinational, double-blind, ...
(Date:5/19/2013)... , May 20, 2013  Whole-cell pertussis vaccines were ... vaccines during a large recent outbreak, according to a ... Whole-cell pertussis vaccines, also called DTwP, were available from ... concerns that ultimately led to the development of acellular ... late 1990s, the United States ...
Breaking Medicine Technology:TNI BioTech, Inc. Stock to Begin Trading on the OTCQB Marketplace 2TNI BioTech, Inc. Stock to Begin Trading on the OTCQB Marketplace 3AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 2AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 3AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 5AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 6Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 2Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 3Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 4
... 2012  Covance Inc. (NYSE: CVD ) said ... repurchase of up to $300 million of its outstanding ... approximately 800,000 shares remaining under a previously-announced repurchase authorization ... common stock. Any purchases under this buyback would be ...
... leading medical practice providing specialized infertility treatment since 1986, ... test that will replace daily blood tests needed to ... Boston IVF has proven that the hormone estradiol, traditionally ... in saliva, virtually eliminating the need for daily blood ...
Cached Medicine Technology:Covance Board Authorizes $300 Million Stock Buyback 2Boston IVF Pioneers World's First Needle-Free Saliva Test Used in Infertility Treatment; Patient Friendly Monitoring Replaces Daily Blood Tests 2Boston IVF Pioneers World's First Needle-Free Saliva Test Used in Infertility Treatment; Patient Friendly Monitoring Replaces Daily Blood Tests 3
... Keeler Galilean loupes are ideal ... when increased magnification and a large ... loupes are laser aligned, lightweight and ... ,Fixed working distance and superior depth ...
U tip irrigation-aspiration cannual designed for manual removal of 12 oclock cortex. 23 gauge thin wall irrigation and aspiration lines for maximum aspiration capabilities. Polished finish. Overall l...
... pneumatic stools come with five legs ... of 18" to 25" (total vertical ... hard rubber castors. Comfortable, durable and ... vinyl as standard, other colors available ...
Anterior Stromal Puncture Cannula, 25 g. For treatment of recurrent corneal erosion. Overall length 24 mm. 5/box....
Medicine Products: